Olanzapine


Description

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent.[

Read more

Pharmacology

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia... Read more

Pharmacodynamic

The effect of olanzapine in the D2 receptor is reported to produce the positive effects of this drug... Read more

Mechanism of action

The activity of olanzapine is achieved by the antagonism of multiple neuronal receptors including th... Read more

Absorption

Olanzapine presents a linear pharmacokinetic profile and, after daily administration, it reaches ste... Read more

Protein binding

Olanzapine is largely bound to plasma proteins and hence, about 93% of the administered dose is boun... Read more

Volume of distribution

The volume of distribution of olanzapine is reported to be of 1000 liters which indicate a large dis... Read more

Clearance

The mean clearance rate of olanzapine is of 29.4 L/hour however, some studies have reported an appar... Read more

Half life

Olanzapine presents a half-life ranging between 21 to 54 hours with an average half-life of 30 hours... Read more

Route of elimination

Olanzapine is mainly eliminated through metabolism and hence, only 7% of the eliminated drug can be... Read more

Toxicity

The toxicity symptoms of olanzapine are known to include somnolence, mydriasis, blurred vision, resp... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Any extrapyramidal events US
  • adult
  • Kind: experimental
    • Percent: 15-32%
  • Kind: placebo
    • Percent: 16%
  • Clinical Trial
    Somnolence US
    • adult
  • Kind: experimental
    • Percent: 29%
  • Kind: placebo
    • Percent: 13%
  • Clinical Trial
    Parkinsonism events US
    • adult
  • Kind: experimental
    • Percent: 8-20%
  • Kind: placebo
    • Percent: 10%
  • Clinical Trial
    Joint Pain US
    • adult
  • Kind: experimental
    • Percent: 12%
  • Kind: placebo
    • Percent: 8%
  • Clinical Trial
    Insomnia US
    • adult
  • Kind: experimental
    • Percent: 12%
  • Kind: placebo
    • Percent: 11%
  • Clinical Trial
    Accidental injury US
    • adult
  • Kind: experimental
    • Percent: 12%
  • Kind: placebo
    • Percent: 8%
  • Clinical Trial
    Akathisia events US
    • adult
  • Kind: experimental
    • Percent: 5-11%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Dizziness US
    • adult
  • Kind: experimental
    • Percent: 11%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Asthenia US
    • adult
  • Kind: experimental
    • Percent: 10%
  • Kind: placebo
    • Percent: 9%
  • Clinical Trial
    Constipation US
    • adult
  • Kind: experimental
    • Percent: 9%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Dry Mouth US
    • adult
  • Kind: experimental
    • Percent: 9%
  • Kind: placebo
    • Percent: 5%
  • Clinical Trial
    Rhinitis US
    • adult
  • Kind: experimental
    • Percent: 7%
  • Kind: placebo
    • Percent: 6%
  • Clinical Trial
    Dyspepsia US
    • adult
  • Kind: experimental
    • Percent: 7%
  • Kind: placebo
    • Percent: 5%
  • Clinical Trial
    Abnormal Gait US
    • adult
  • Kind: experimental
    • Percent: 6%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Increased cough US
    • adult
  • Kind: experimental
    • Percent: 6%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Fever US
    • adult
  • Kind: experimental
    • Percent: 6%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Somnolence US
    • adult
  • Kind: experimental
    • Percent: 6%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Somnolence US
    • adult
  • Kind: experimental
    • Percent: 6%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Residual events US
    • adult
  • Kind: experimental
    • Percent: 1-5%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Weight Gain US
    • adult
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Extremity pain US
    • adult
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Ecchymosis US
    • adult
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Back Pain US
    • adult
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Tremor US
    • adult
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Vomiting US
    • adult
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Any extrapyramidal events US
    • adult
  • Kind: experimental
    • Percent: 0-4%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Parkinsonism events US
    • adult
  • Kind: experimental
    • Percent: 0-4%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Dizziness US
    • adult
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Dizziness US
    • adult
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Dystonic events US
    • adult
  • Kind: experimental
    • Percent: 2-3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Peripheral Edema US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Akathisia US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Hypertonia US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Ambylopia US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Increased appetite US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Tachycardia US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Postural Hypotension US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Chest Pain US
    • adult
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Urinary Tract Infection US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Articulation impairment US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Urinary Incontinence US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Asthenia US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Hypertension US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Akathisia events US
    • adult
  • Kind: experimental
    • Percent: 0-2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Hypotension US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Asthenia US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Hypotension US
    • adult
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Increased alkaline phosphatase US
    • adult
  • Kind: experimental
    • Percent: >1%
  • Clinical Trial
    Tremor US
    • adult
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial
    Tremor US
    • adult
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 0%
  • Clinical Trial

    Contraindications

    Information currently not available.

    Food Interactions

    • Avoid alcohol.
    • Take without regard to meals.

    Interactions

    Type in a drug name to check for interaction with Olanzapine

    The metabolism of (R)-warfarin can be decreased when combined with Olanzapine.
    The metabolism of (S)-Warfarin can be decreased when combined with Olanzapine.
    The metabolism of Olanzapine can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
    The therapeutic efficacy of Olanzapine can be decreased when used in combination with 1,10-Phenanthroline.
    The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Olanzapine.
    The therapeutic efficacy of Olanzapine can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.
    The therapeutic efficacy of Olanzapine can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.
    The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Olanzapine.
    The therapeutic efficacy of Olanzapine can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.
    The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Olanzapine.
    The risk or severity of adverse effects can be increased when Olanzapine is combined with 4-hydroxycoumarin.
    The risk or severity of adverse effects can be increased when Olanzapine is combined with 4-Methoxyamphetamine.
    The risk or severity of adverse effects can be increased when Olanzapine is combined with 5-methoxy-N,N-dimethyltryptamine.
    The metabolism of 6-O-benzylguanine can be decreased when combined with Olanzapine.
    The risk or severity of adverse effects can be increased when Olanzapine is combined with 7-Nitroindazole.
    The risk or severity of adverse effects can be increased when Olanzapine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
    The metabolism of 8-azaguanine can be decreased when combined with Olanzapine.
    The metabolism of 8-chlorotheophylline can be decreased when combined with Olanzapine.
    The metabolism of 9-Deazaguanine can be decreased when combined with Olanzapine.
    The metabolism of 9-Methylguanine can be decreased when combined with Olanzapine.

    References

    • 1 . Chelkeba L, Gidey K, Mamo A, Yohannes B, Matso T, Melaku T: Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Pharm Pract (Granada). 2017 Jan-Mar;15(1):877. doi: 10.18549/PharmPract.2017.01.877. Epub 2017 Mar 15. [PubMed: 28503222]
    • 2 . Martel ML, Klein LR, Rivard RL, Cole JB: A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department. Acad Emerg Med. 2016 Jan;23(1):29-35. doi: 10.1111/acem.12842. Epub 2015 Dec 31. [PubMed: 26720055]
    • 3 . Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y: Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017 Jul;83(7):1369-1379. doi: 10.1111/bcp.13242. Epub 2017 Mar 23. [PubMed: 28112422]
    • 4 . Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC: Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013 Aug 1;14:38. doi: 10.1186/2050-6511-14-38. [PubMed: 23902726]
    • 5 . Malhotra K, Vu P, Wang DH, Lai H, Faziola LR: Olanzapine-Induced Neutropenia. Ment Illn. 2015 Jun 23;7(1):5871. doi: 10.4081/mi.2015.5871. eCollection 2015 Feb 24. [PubMed: 26266027]
    • 6 . Thomas K, Saadabadi A: Olanzapine . [PubMed: 30422498]
    • 7 . Chue P, Singer P: A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci. 2003 Jul;28(4):253-61. [PubMed: 12921220]
    • 8 . Green W. (2001). Child & adolescent clinical psychopharmacology (3rd ed.). Lippincott Williams & Wilkins.
    • 9 . Ng C., Lin K., Singh B. and Chiu E. (2008). Ethno-psychopharmacology. Cambridge University Press.
    • 10 . Schatzberg A. and Nemeroff C. (2017). The american psychiatric association publishing textbook of psychopharmacology (5th ed.). American Psychiatric Association Publishing.
    • 11 . Canadian Mental Health Association [Link]
    • 12 . NIH [Link]
    • 13 . Mylan-Olanzapine. Product monograph [Link]

    Recent Questions